Related Experiment Video
Updated: Oct 10, 2025
11:00
Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment
Published on: March 25, 2020
17.3K
Charting the tumor antigen maps drawn by single-cell genomics.
Caleb A Lareau1, Kevin R Parker2, Ansuman T Satpathy1
1Department of Pathology, Stanford University, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Cancer Cell
|December 15, 2021
Summary
Antibody specificity drives cancer immunotherapies like CAR T-cells. Integrating genomics can identify better targets and reduce side effects for precision medicine.
Area of Science:
- Immunology
- Genomics
- Oncology
Background:
- Antibodies are crucial for precision cancer immunotherapies, such as chimeric antigen receptor T-cells and antibody-drug conjugates.
- Single-cell genomics offers potential for comprehensive antigen expression mapping in human tissues and cancers.
Purpose of the Study:
- To review current immunotherapy antigen targets and their clinical adverse effects.
- To explore using large genomics datasets for de-risking targets and identifying optimal antigens for cancer therapy.
Main Methods:
- Review of existing literature on cancer immunotherapy targets.
- Analysis of single-cell genomics data for antigen expression patterns.
- Evaluation of clinical data on immunotherapy-related adverse effects.
Main Results:
- Current immunotherapies rely on antibody specificity for targeted cancer treatment.
- Genomics data can reveal potential off-target toxicities and guide the selection of safer, more effective antigens.
- Integrating diverse datasets can improve the precision and safety of cancer immunotherapies.
Conclusions:
- Optimizing antigen selection through genomics is key to advancing precision cancer immunotherapy.
- Reducing adverse effects by de-risking targets will enhance therapeutic efficacy and patient outcomes.
- Future immunotherapies can benefit from a data-driven approach to antigen discovery and validation.
